Are you Dr. Wang?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2201 Inwood Rd
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-2615
Summary
- Dr. Jue Wang, MD is an oncologist in Dallas, Texas. He is currently licensed to practice medicine in Texas and Arizona. He is an Assistant Professor at University of Nebraska Medical.
Certifications & Licensure
AZ State Medical License 2014 - 2025
TX State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Successful Management of Disseminated Intravascular Coagulation in Metastatic Castrate-Resistant Prostate Cancer With Lutetium-177: A Case Report and Review of the Lit...Jie Zheng, Chidera Ibezue, Nghi Nguyen, Qi Cai, Qian Qin
Cureus. 2024-12-01 - On reactive Ion Etching of Parylene-C with Simple Photoresist Mask for Fabrication of High Porosity Membranes to Capture Circulating and Exfoliated Tumor Cells.Inad Rabadi, David Carpentieri, Jue Wang, Frederic Zenhausern, Jian Gu
Micromachines. 2024-04-13 - 3 citationsTrastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.Roisin M Connolly, Victoria Wang, David M Hyman, Petros Grivas, Edith P Mitchell
Clinical Cancer Research. 2024-04-01
Press Mentions
Comparison of Clinicopathological Characteristics and Response to Neoadjuvant Systemic Therapy in Patients with HER2-Low-Positive and HER2-Zero Breast CancerJanuary 19th, 2023
NMPA Approves IND Application for CT103A, a Fully-Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-Developed by IASO BIO and Innovent BiologicsOctober 2nd, 2019- Clinical Results of Fully Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-Developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual MeetingsJune 19th, 2019
- Join now to see all
